_edited_edited.png)
Jason B. Gibbons, Ph.D.
Health Economist
Postdoctoral Fellow
Johns Hopkins University
Bloomberg School of Public Health
Department of Health Policy & Management
Research Interests
- Mental Health and Substance Use Disorders
- Pharmaceutical Markets & Competition
Hello! I am Jason
I am a health economist with a methodological background in econometrics, industrial organization economics, epidemiology, and machine learning. My research is focused on evaluating health policies and programs related to mental health and substance use disorder treatment and pharmaceutical markets and competition.
EDUCATION
2021-
Postdoctoral Fellow
Johns Hopkins Bloomberg School of Public Health
Department of Health Policy & Management
2017-2021
PhD
Health Services Organization & Policy (Economics Cognate)
University of Michigan School of Public Health
Ann Arbor, MI
Dissertation Title:
Competition, Adherence, and Racial & Ethnic Disparities in the Medication-Assisted Treatment Market for Opioid Use Disorder
Dissertation Committee:
Edward Norton, Ph.D. (Co-Chair)
Jeffrey McCullough, Ph.D. (Co-Chair)
Kara Zivin, Ph.D., MS
Zach Brown, Ph.D.
2011-2015
BA with Honors
Economics
University of Chicago
Chicago, IL
RESEARCH
Publications, Working Papers, & Research in Progress
PUBLICATIONS
Journal Articles
2022 Jason B Gibbons, Elizabeth A Stuart, Brendan Saloner. “Methadone on Wheels—A New Option to Expand Access to Care Through Mobile Units.” JAMA Psychiatry. March 3, 2022. doi:10.1001/jamapsychiatry.2021.3716
2022 Jason B Gibbons, Jeffrey S McCullough, Kara Zivin, Zach Y Brown, Edward C Norton, “The Association between Buprenorphine Nonadherence, Opioid Overdose, and Health Care Spending." JAMA Psychiatry. October 05, 2022. doi:10.1001/jamapsychiatry.2022.3118
2022 Jason B Gibbons, Chiang-Hua Chang, Mousumi Banerjee, Edward C Norton, Jennifer Meddings, and Julie PW Bynum. "Small Practice Participation and Performance in the Medicare Accountable Care Organizations." American Journal of Managed Care, March 2022, 28(3):117- 123. https://doi.org/10.37765/ajmc.2022.88839.
2022 Jason B Gibbons, Edward C Norton, Jeffrey S McCullough, Jill Lavigne, David O Meltzer, Virginia Fiedler, and Robert D Gibbons. “The Association between Vitamin D Supplementation and Infection with COVID-19.” Nature - Scientific Reports, 12, 19397 (2022). https://doi.org/10.1038/s41598-022-24053-4
2022 Jason B Gibbons, Jennifer Meddings (Co-first Author), Chiang-Hua Chang, Mousumi Banerjee, Edward C Norton, and Julie PW Bynum. "The Impact of Nurse Practitioner Care and ACO Assignment on Skilled Nursing Services and Hospital Readmissions.” Forthcoming, Medical Care.
2022 Jason B Gibbons, Mica Laber, and Charles Bennett. “Humira: The First $20 Billion Drug.” Forthcoming, American Journal of Managed Care.
2022 Anaeze C Offodile, Jason B Gibbons, Samantha Murrell, Donna Kinzer, and Joshua M Sharfstein. “A Global Equity Model (GEM) for the Advancement of Community Health and Health Equity.” National Academy of Medicine Perspectives. November 14, 2022. https://doi.org/10.31478/202211b.
2022 Jill E Lavigne and Jason B Gibbons.[1] “Association between Vitamin D Supplementation and Suicide Attempts in a Population of United States Veterans.” Forthcoming, PLOS One.
2022 Loren Saulsberry, Ankur Bhargava, Sharon Zeng, Jason B Gibbons, Cody Brannan, Diane S. Lauderdale, and Robert D. Gibbons. “The Social Vulnerability Metric (SVM) As A New Tool for Public Health.” Health Services Research. November 2022. https://doi.org/10.1111/1475-6773.14102
Book Chapters
2022 Brendan Saloner and Jason B Gibbons. “Access for Treatment for Opioid Use Disorder.” Oxford Handbook of Opioids and Opioid Use Disorder. Forthcoming, March 2023.
ARTICLES UNDER PEER-REVIEW
2022 Jason B Gibbons, Charles L Bennett, and Gerard Anderson. “Ibrutinib – Ten Years On.” Under Review at American Journal of Managed Care.
2022 Jason B Gibbons, Samantha J Harris, Keisha Soloman, Olivia Sugarman, Carlos Hardy, Elizabeth A Stuart, and Brendan Saloner. “The Rising Tide of Overdose Deaths among Black Americans: A Review of the Literature.” Under Review at Lancet Psychiatry.
2022 Jill E Lavigne, Kwan Hur, Jason B Gibbons, and Wilfred R Pigeon, “Comparative Safety of Insomnia Medications and Suicide Death in Veterans.” Under Review at Pharmacoepidemiology & Drug Safety
2022 Atharva Bhagwat, Kadija Ferryman, and Jason B Gibbons.[2] “Opioid Risk Scoring in Prescription Drug Monitoring Programs – Implications for Opioid Use Disorder Treatment and Policy.” Under Review at Nature Medicine.
2022 Kiefer Ahn, Antonio Trujillo, Jason B Gibbons, Charles L Bennett, and Gerard Anderson. “Do Patent Litigation Settlements Protect Weak Patents for Drugs?” Under Review at International Review of Law and Economics.
2022 Keisha Solomon, Jason O’Connor, Jason B Gibbons, Kenneth A Feder, Evan S Cole, Austin Kilaru, Brendan Saloner, Elizabeth A Stuart, and Julie M Donohue. “Association of a quality improvement program targeting opioid overdose patients in the emergency department with subsequent initiation of treatment for opioid use disorder.” Revise & Resubmit at JAMA Health Forum.
[1] Senior Author
[2] Senior Author
WORKING PAPERS
2022 Jason B Gibbons, Wenshu Li, Matthew Eisenberg, Elizabeth A Stuart, and Brendan Saloner. “Can Mobile Methadone Expand Access to Opioid Use Disorder Treatment? A Simulation Study using Louisiana Medicaid Data.”
2022 Jason B Gibbons, Mark Meiselbach, Gerard F Anderson, Joseph Ross, and Ge Bai. “Understanding Social Determinants of Health: A National Landscape Study.”
2022 Valencia Lyle, Samantha Harris, Omeid Heidari, Kate Boulton, Eric Hulsey, Brendan Saloner, Jason Gibbons.[3] “The Association between High-Threshold Opioid Use Disorder Treatment Practices and Buprenorphine Prescriber Care Termination Rates.”
2022 Anaeze C Offodile, Jason B Gibbons, Samantha Murrell, Donna Kinzer, and Joshua M Sharfstein. “Can Global Payment Models Improve Health Equity? A Review of The Global Equity Model.”
2021- Jason B Gibbons, Jeffrey S McCullough, Zach Brown, Kara Zivin, and Edward C Norton. "Health Consequence of Strategic Entry Delay in the Pharmaceutical Industry: The Effect of the Suboxone Product Hop on Adverse Opioid Events."
2021- Jason B Gibbons, Jeffrey S McCullough, Zach Brown, Kara Zivin, and Edward C Norton. "Racial and Ethnic Disparities in the Medication Assisted Treatment Market for Opioid Use Disorder."
2021- Yiran Wang and Jason B Gibbons.[4] "Merger Mania Revisited: The Effect of Generic Pharmaceutical Mergers on Drug Prices."
RESEARCH IN PROGRESS
2022 Mariana Socal, Jason B Gibbons, Mike DiStefano, Jennifer Hsu, Joseph Hydell, and Celia Proctor. “Coupon Hops – Do Brand Manufacturers use Coupons to Facilitate Product Hops?”
2022 Jason B Gibbons, Samantha J Harris, Esita Patel, Elizabeth A Stuart, and Eric G Hulsey. A Qualitative Evaluation of Advances in Emergency Department Opioid Use Disorder Care in Michigan
2022 Jason B Gibbons, Antonio Trujillo, Charles Bennett, and Manuel Hermosillo. “Do Pharmaceutical Manufacturer Coupons Strengthen Brand Loyalty?”
2022 Antonio Trujillo, Jason B Gibbons, Charles Bennett, and Gerard Anderson, “The Effect of Paragraph IV Litigation Settlements on Consumer Spending.”
2022 Lane Davis and Jason B Gibbons. “The Association between Individual Characteristics, Social Determinants of Health, and Outpatient Opioid Use Disorder Treatment Dropout.”
[3] Senior Author
[4] Senior Author
EXPERIENCE
2021-
Postdoctoral Fellow
Baltimore, MD
Johns Hopkins Bloomberg Opioid Initiative
-
Evaluated the impact of state-level opioid policy initiatives on opioid use disorder treatment rates. Examples of research include evaluating opioid use disorder treatment implementation in Michigan hospital emergency departments, simulating the treatment impact of expanding mobile methadone clinics in Louisiana, and estimating treatment and health outcomes following the Hospital Quality Improvement Program in Pennsylvania.
2020-2021
WOC Research Affiliate
Canadaigu, NY
US Department of Veterans Affairs - Center of Excellence for Suicide Research
-
Worked with Dr. JIll Lavigne on research related to the comparative effectiveness of insomnia medications and the association between suicidality and infection with COVID-19, and the potential for the use of folic acid and Vitamin D to prevent suicide attempts. Applied for a VA grant related to our work on insomnia, which is under review.
2019-2021
Research Assistant
Ann Arbor, MI
Michigan Department of Health and Human Services
-
Evaluated trends in substance use disorder treatment capacity in Michigan’s Medicaid program using Medicaid claims data. Additional areas of research included racial and ethnic disparities in substance use disorder treatment, opportunities to expand utilization of Medication Assisted Treatments to primary care physicians, and reimbursement variation for services by setting and geography.
2017-2021
Research Assistant
Ann Arbor, MI
University of Michigan Institute for Health Policy & Innovation
-
Worked with Dr. Lena Chen, Dr. Edward Norton, Dr. Julie Bynum, Dr. Mousumi Banerjee, Dr. Jennifer Meddings, and Dr. Chiang-Hua Chang to study post-acute care in Affordable Care Organizations. Additional research areas included spending variation between small vs. large practices in ACOs, hospital participation and dropout in CMS’s comprehensive joint replacement program, effects of physician mobility on patient health, and care delivery in hospitals contracting with national provider practices.
2018-2021
WOC Research Assistant
Ann Arbor, MI
US Department of Veterans Affairs - Ann Arbor Veterans Health Administration
-
Worked with Dr. Jeffrey McCullough, Dr. Neil Mehta, and Dr. Jeremy Sussman to study treatment heterogeneity across A1C medications for a population of US veterans. Used random causal forests to explore variation in efficacy across patient demographics and patient health measures collected from VA EHR data .
2015-2017
Analyst
Boston, MA
Greylock McKinnon Associates
-
Assisted PhD expert witnesses to calculate legal damages in pharmaceutical litigation relating to pharmaceutical antitrust and fraud. The primary types of cases included Brand to Generic “pay for delay,” off-label promotion of pharmaceuticals, and Medicare/Medicaid billing fraud. Work responsibilities included statistical analysis and economic modeling of medical and pharmaceutical claims data in SAS & STATA, review of litigation discovery materials using legal databases, and assisting with the drafting of expert witness reports and testimony. My analyses and research were regularly used in high profile cases against US Fortune 500 pharmaceutical corporations.
2014
Intern
Boston, MA
Massachusetts Health Policy Comission
-
Executed a pilot study that examined consumer choice on the Massachusetts State Health Exchange. Analyzed public exchange data to show how plan premiums varied across network breadth and plan tiers. Results published in the Massachusetts Health Policy Commission’s 2014 Cost Trends Report.
TEACHING
2020
Health Economics (Masters), Microeconomic Theory (Undergraduate)
Role: Virtual Education Instructor
Viax Education Online
2019
Health Care Finance (Masters)
Role: Graduate Student Instructor
University of Michigan School of Public Health
Teaching Interests: Health Economics, Healthcare Finance, Applied Econometrics, Microeconomic Theory
Programming SKILLS
SAS
STATA
MATLAB
R
PYTHON
SQL
EXPERTISE
I am an Economist
I completed the Ph.D. coursework in Industrial Organization, Labor Economics, Econometrics, and Microeconomics as a part of my graduate training. I use structural economic models in my research.
I am a Big Data Scientist
I am familiar with the application of cutting edge Machine Learning methods. I am an expert in the analysis of medical claims data and electronic health records.
I am a Health Policy Researcher
I use econometrics and counterfactual analyses to determine the effectiveness of health care policy and national programs in improving population health and reducing health care expenditures.
